Home›Stock Screener›Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Share Price Today | Stock Price & Lincoln Pharmaceuticals Share Screener

LINCOLN Pharmaceuticals & Biotechnology
Live Share Price NSE
₹514.45
▼ -6.05 (-1.16%)
2026-11-18 00:00:00
Live Share Price BSE
₹513.65
▼ -6.30 (-1.21%)
2026-11-18 00:00:00

As of November 18, 2026, the live Lincoln Pharmaceuticals share price (NSE: LINCOLN) is ₹514.45 on NSE and ₹513.65 on BSE, down 1.16% from the previous close, with shares trading between ₹510.00 and ₹523.40 in today's trading session, and a 52-week range of ₹444.20–₹758.15. Track Lincoln Pharmaceuticals networth to gauge the company's total market size. Use the Lincoln Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Lincoln Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹183 and net income of ₹12, with EBITDA of ₹21, an operating margin of 13.0% and a profit margin of 6.6%.

Lincoln Pharmaceuticals Market Cap ₹1,043.85 Cr.
LINCOLN P/E Ratio (TTM) 10.80
Lincoln Pharmaceuticals P/B Ratio 1.29
EPS (TTM) ₹43.88
Dividend Yield 0.34%
Debt to Equity -
LINCOLN 52 Week High ₹758.15
Lincoln Pharmaceuticals 52 Week Low ₹444.20
Operating Margin 13.00%
Profit Margin 6.56%
LINCOLN Revenue (TTM) ₹183.00
EBITDA ₹21.00
Net Income ₹12.00
Total Assets ₹890.00
Total Equity ₹758.00

Lincoln Pharmaceuticals Share Price Chart

Track the current stock price of Lincoln Pharmaceuticals with an interactive chart. Analyse LINCOLN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Lincoln Pharmaceuticals stock quote in one place.

The quote of ₹514.45 sits between the 52-week low of ₹444.20 and the 52-week high of ₹758.15, and the latest session moved -1.16% from the previous close.

Lincoln Pharmaceuticals Company Profile - Fundamental Screener

Screen Lincoln Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LINCOLN shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE405C01035.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE405C01035

Lincoln Pharmaceuticals Balance Sheet Screener

Screen LINCOLN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹890, up from ₹797 in 2025.

Latest statistics put total assets at ₹890 and shareholder funds at ₹758.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 890 797 700 587 534 452 389 366 347 305
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 191 182 179 151 132 111 123 121 117 103

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 22 19 15 13 11 10 10 11 18 22
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 758 672 593 503 433 366 314 270 225 193
Share Capital 20 20 20 20 20 20 20 20 20 20
Reserves & Surplus 738 652 573 482 413 346 293 249 204 172

Lincoln Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Lincoln Pharmaceuticals income statement and profit fundamentals. Analyze LINCOLN quarterly results. Lincoln Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹183 and net profit was ₹12, equal to earnings per unit of ₹5.81, at an operating margin of 13%.

In that period expenses were ₹162, interest cost ₹0 and tax ₹5. The next period listed, 2026-Jun, shows revenue of ₹202 and net profit of ₹36.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 183 202 201 161 169 171 182 150 158 171 156 116 143 165 158
Expenses 162 150 168 142 130 138 143 124 125 133 123 96 115 125 117

Operating Costs and Margins

EBITDA 21 52 33 20 39 33 39 25 33 38 33 21 28 40 41
Operating Profit % 13.00% 15.00% 12.00% 16.00% 15.00% 16.00% 14.00% 13.00% 15.00% 18.00% 16.00% 15.00% 15.00% 20.00% 20.00%
Depreciation 4 4 4 3 4 4 4 3 3 3 3 2 3 3 3
Interest 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0

Profit and Earnings

Profit Before Tax 17 48 29 16 35 29 35 22 30 35 29 17 26 37 38
Tax 5 11 9 5 8 9 6 4 6 8 8 4 6 9 10
Net Profit 12 36 20 12 28 20 29 19 24 26 21 13 19 28 28
EPS 5.81 18.09 10.20 5.78 13.82 9.98 14.28 9.28 11.82 13.15 10.37 6.27 9.49 13.81 14.00

Lincoln Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen LINCOLN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹106, and net cash flow was an inflow of ₹8.

Over the same period, investing activities used ₹98 and financing activities provided ₹0.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 106 93 63 39 76 69 75 53 27 25
Investing Activities -98 -79 -57 -37 -78 -64 -31 -18 -12 -26

Financing and Net Cash

Financing Activities 0 -6 -5 -5 -3 -6 -38 -36 -11 0
Net Cash Flow 8 8 1 -2 -5 -1 7 -1 4 0

Lincoln Pharmaceuticals Shareholding Pattern Screener

See Lincoln Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Lincoln Pharmaceuticals promoter holding and ownership changes for LINCOLN on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 49.78%, foreign institutions 5.19%, domestic institutions 1.09% and the public 34.70%, spread across 28,303 shareholders.

The shareholder count was 28,303 in 2026-Mar, compared with 29,396 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 49.78% 49.78% 49.78% 49.78% 49.78% 49.78% 49.78% 49.53%

Institutional Investors

FII Holding 5.19% 4.60% 4.55% 5.00% 5.14% 4.72% 4.70% 3.93%
DII Holding 1.09% 0.27% 0.02% 0.01% 0.01% 0.01% 0.01% 0.05%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 34.70% 36.12% 36.48% 36.64% 36.27% 36.26% 36.29% 37.36%
Other Holding 9.24% 9.24% 9.17% 8.59% 8.81% 9.23% 9.23% 9.13%
Shareholder Count 28,303 29,396 29,272 31,867 31,784 32,370 31,026 31,375

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Lincoln Pharmaceuticals. Lincoln Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹1.80 per unit for 2026-March, a yield of 0.34%, compared with ₹1.80 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹1.80, ₹1.80 and ₹1.80 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹1.80 0.34%
2025-March ₹1.80 0.32%
2024-March ₹1.80 0.33%
2023-March ₹1.50 0.26%
2022-March ₹1.50 0.44%
2021-March ₹1.50 0.48%
2020-March ₹1.50 0.67%
2019-March ₹1.50 1.16%
2018-March ₹1.50 0.71%
2017-March ₹1.20 0.56%

Lincoln Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Lincoln Pharmaceuticals stock. Check LINCOLN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 2 indices, including BSE INDEX BSE HC.

Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE INDEX BSE HC
BSE INDEX SMLCAP

Lincoln Pharmaceuticals Market Events Screener - Corporate Actions

Get Lincoln Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Lincoln Pharmaceuticals stock events that may affect LINCOLN share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 29, 2026, with a record date of October 29, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Dividend dated September 11, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-29 2026-10-29 Quarterly Result Announcement NA 8.19%
2026-09-30 2026-09-30 Annual General Meeting NA -5.30%
2026-09-11 2026-09-11 Dividend ₹ 1.80 /share -16.09%
2026-08-13 2026-08-13 Quarterly Result Announcement NA -2.71%
2026-05-28 2026-05-28 Quarterly Result Announcement NA 17.56%
2026-02-12 2026-02-12 Quarterly Result Announcement NA 10.57%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 0.52%
2025-09-30 2025-09-30 Annual General Meeting NA -2.11%
2025-09-12 2025-09-12 Dividend ₹ 1.80 /share -7.23%
2025-08-07 2025-08-07 Quarterly Result Announcement NA -2.07%
2025-05-22 2025-05-22 Quarterly Result Announcement NA 2.21%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -4.25%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -5.02%
2024-09-30 2024-09-30 Annual General Meeting NA -4.13%
2024-09-13 2024-09-14 Dividend ₹ 1.80 /share 28.22%

Lincoln Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen LINCOLN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Lincoln Pharmaceuticals Company Announcements - News & Reports Screener

Screen LINCOLN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 30, 2026.

The next most recent announcements are dated October 29, 2026 and October 29, 2026.

Date Update Actions
2026-10-30 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-29 Un-Audited Financial Results For The Quarter And Half Year Ended On September 30 2026. -
2026-10-29 Board Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter And Half Year Ended On September 30 2026. -
2026-10-22 Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30.09.2026. -
2026-10-17 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-16 Minutes Of 32Nd Annual General Meeting Of The Company -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-03 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-24 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-24 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-23 Closure of Trading Window -
2026-09-07 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-05 Update Regarding Dispatch Of Physical Communication To Shareholders To Access Annual Report Of The Company. -
2026-09-05 Reg. 34 (1) Annual Report. -
2026-09-05 Notice Of 32Nd Annual General Meeting Of The Company. -
2026-08-29 Intimation Of Book Closure And Record Date For The Purpose Of 32Nd Annual General Meeting And Final Dividend For The Financial Year 2025-26. -
2026-08-29 Corporate Action-Fixes Book Closure For Determining The Dividend If Approved At The AGM -
2026-08-26 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹514.45, within a 52-week range of ₹444.20 to ₹758.15. The P/E ratio is 10.80 and the P/B ratio is 1.29, with earnings per unit of ₹43.88. Market capitalisation stands at ₹1,043.85 Cr and the dividend yield is 0.34%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 18, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.